Dysregulation of sphingolipid metabolism in cancer

Cancer Biology and Therapy

Volumn 11, Issue 2, 2011, Pages 138-149

  Ryland, Lindsay K ^a   Fox, Todd E ^a   Liu, Xin ^a   Loughran, Thomas P ^a   Kester, Mark ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Ceramide; Ceramide kinase; Dihydroceramide; Glucosylceramide synthase; Sphingolipid; Sphingosine kinase; Sphingosine 1 phosphate

Indexed keywords

ABC294640; ACID CERAMIDASE; CERAMIDE; CERAMIDE GLUCOSYLTRANSFERASE; DESIPRAMINE; ENZYME; FINGOLIMOD; FUMONISIN B1; GALACTOSYLCERAMIDE; GANGLIOSIDE GD2; GANGLIOSIDE GD3; GANGLIOSIDE GM2; GW4869; LCL204; LCL385; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; N OLEOYLETHANOLAMINE; SAFINGOL; SERINE PALMITOYLTRANSFERASE; SPHINGANINE; SPHINGOLIPID; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE 1; SULFATIDE; THERMOZYMOCIDIN; TRICYCLO[4.3.0.1]DECAN 9 YL XANTHOGENATE; TUMOR MARKER; UNCLASSIFIED DRUG;

BIOCHEMISTRY; BLADDER CANCER; CANCER GROWTH; COLON CARCINOMA; GLIOMA; HUMAN; LEUKEMIA; LIPID METABOLISM; LYMPHOMA; MASS SPECTROMETRY; METABOLIC REGULATION; METABOLITE; OSTEOSARCOMA; PATHOGENESIS; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE CARCINOMA; REVIEW; SOLID TUMOR; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; FORECASTING; HUMANS; NEOPLASMS; SPHINGOLIPIDS;

EID: 78751518056     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.2.14624     Document Type: Review

References (207)

1. Segui B, Andrieu-Abadie N, Jaffrezou JP, Benoist H, Levade T. Sphingolipids as modulators of cancer cell death: potential therapeutic targets. Biochim Biophys Acta 2006; 1758:2104-20.
2. Zheng W, Kollmeyer J, Symolon H, Momin A, Munter E, Wang E, et al. Ceramides and other bioactive sphingolipid backbones in health and disease: lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy. Biochim Biophys Acta 2006; 1758:1864-84.
3. Leong WI, Saba JD. S1P metabolism in cancer and other pathological conditions. Biochimie 2010; 92:716-23.
4. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004; 4:604-16.
5. Fyrst H, Saba JD. An update on sphingosine-1-phosphate and other sphingolipid mediators. Nat Chem Biol 6:489-97.
6. Saddoughi SA, Song P, Ogretmen B. Roles of bioactive sphingolipids in cancer biology and therapeutics. Subcell Biochem 2008; 49:413-40.
7. Spiegel S. Sphingosine 1-phosphate: a prototype of a new class of second messengers. J Leukoc Biol 1999; 65:341-4.
8. Zitomer NC, Mitchell T, Voss KA, Bondy GS, Pruett ST, Garnier-Amblard EC, et al. Ceramide synthase inhibition by fumonisin B1 causes accumulation of 1-deoxysphinganine: a novel category of bioactive 1-deoxysphingoid bases and 1-deoxydihydroceramides biosynthesized by mammalian cell lines and animals. J Biol Chem 2009; 284:4786-95.
9. Yin J, Miyazaki K, Shaner RL, Merrill AH Jr, Kannagi R. Altered sphingolipid metabolism induced by tumor hypoxia -new vistas in glycolipid tumor markers. FEBS Lett 2010; 584:1872-8.
10. Merrill AH Jr, Wang MD, Park M, Sullards MC. (Glyco)sphingolipidology: an amazing challenge and opportunity for systems biology. Trends Biochem Sci 2007; 32:457-68.
11. Kolesnick RN, Kronke M. Regulation of ceramide production and apoptosis. Annu Rev Physiol 1998; 60:643-65.
12. Okazaki T, Kondo T, Kitano T, Tashima M. Diversity and complexity of ceramide signalling in apoptosis. Cell Signal 1998; 10:685-92.
13. Pushkareva M, Obeid LM, Hannun YA. Ceramide: an endogenous regulator of apoptosis and growth suppression. Immunol Today 1995; 16:294-7.
14. Taha TA, Mullen TD, Obeid LM. A house divided: ceramide, sphingosine and sphingosine-1-phosphate in programmed cell death. Biochim Biophys Acta 2006; 1758:2027-36.
15. Ogretmen B, Hannun YA. Updates on functions of ceramide in chemotherapy-induced cell death and in multidrug resistance. Drug Resist Updat 2001; 4:368-77.
16. Andrieu-Abadie N, Gouaze V, Salvayre R, Levade T. Ceramide in apoptosis signaling: relationship with oxidative stress. Free Radic Biol Med 2001; 31:717-28.
17. Herr I, Wilhelm D, Bohler T, Angel P, Debatin KM. Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. EMBO J 1997; 16:6200-8.
18. El-Assaad W, Kozhaya L, Araysi S, Panjarian S, Bitar FF, Baz E, et al. Ceramide and glutathione define two independently regulated pathways of cell death initiated by p53 in Molt-4 leukaemia cells. Biochem J 2003; 376:725-32.
19. Nava VE, Cuvillier O, Edsall LC, Kimura K, Milstien S, Gelmann EP, et al. Sphingosine enhances apoptosis of radiation-resistant prostate cancer cells. Cancer Res 2000; 60:4468-74.
20. Scarlatti F, Sala G, Ricci C, Maioli C, Milani F, Minella M, et al. Resveratrol sensitization of DU145 prostate cancer cells to ionizing radiation is associated to ceramide increase. Cancer Lett 2007; 253:124-30.
21. Zhang J, Alter N, Reed JC, Borner C, Obeid LM, Hannun YA. Bcl-2 interrupts the ceramide-mediated pathway of cell death. Proc Natl Acad Sci USA 1996; 93:5325-8.
22. Olshefski RS, Ladisch S. Glucosylceramide synthase inhibition enhances vincristine-induced cytotoxicity. Int J Cancer 2001; 93:131-8.
23. Perry DK, Hannun YA. The role of ceramide in cell signaling. Biochim Biophys Acta 1998; 1436:233-43.
24. Devalapally H, Duan Z, Seiden MV, Amiji MM. Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles. Clin Cancer Res 2008; 14:3193-203.
25. Gu X, Song X, Dong Y, Walters E, Zhang R, Pang X, et al. Vitamin E succinate induces ceramide-mediated apoptosis in head and neck squamous cell carcinoma in vitro and in vivo. Clin Cancer Res 2008; 14:1840-8.
26. Wang XZ, Beebe JR, Pwiti L, Bielawska A, Smyth MJ. Aberrant sphingolipid signaling is involved in the resistance of prostate cancer cell lines to chemotherapy. Cancer Res 1999; 59:5842-8.
27. Bieberich E, Kawaguchi T, Yu RK. N-acylated serinol is a novel ceramide mimic inducing apoptosis in neuroblastoma cells. J Biol Chem 2000; 275:177-81.
28. Bieberich E, Hu B, Silva J, MacKinnon S, Yu RK, Fillmore H, et al. Synthesis and characterization of novel ceramide analogs for induction of apoptosis in human cancer cells. Cancer Lett 2002; 181:55-64.
29. Oh JE, So KS, Lim SJ, Kim MY. Induction of apoptotic cell death by a ceramide analog in PC-3 prostate cancer cells. Arch Pharm Res 2006; 29:1140-6.
30. Crawford KW, Bittman R, Chun J, Byun HS, Bowen WD. Novel ceramide analogues display selective cytotoxicity in drug-resistant breast tumor cell lines compared to normal breast epithelial cells. Cell Mol Biol 2003; 49:1017-23.
31. Nica AF, Tsao CC, Watt JC, Jiffar T, Kurinna S, Jurasz P, et al. Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK. Cell Cycle 2008; 7:3362-70.
32. Mehta S, Blackinton D, Omar I, Kouttab N, Myrick D, Klostergaard J, et al. Combined cytotoxic action of paclitaxel and ceramide against the human Tu138 head and neck squamous carcinoma cell line. Cancer Chemother Pharmacol 2000; 46:85-92.
33. Desai A, Vyas T, Amiji M. Cytotoxicity and apoptosis enhancement in brain tumor cells upon coadministration of paclitaxel and ceramide in nanoemulsion formulations. J Pharm Sci 2008; 97:2745-56.
34. Kim WH, Choi CH, Kang SK, Kwon CH, Kim YK. Ceramide induces non-apoptotic cell death in human glioma cells. Neurochem Res 2005; 30:969-79.
35. Shabbits JA, Mayer LD. High ceramide content liposomes with in vivo antitumor activity. Anticancer Res 2003; 23:3663-9.
36. Stover TC, Sharma A, Robertson GP, Kester M. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin Cancer Res 2005; 11:3465-74.
37. Liu X, Ryland L, Yang J, Liao A, Aliaga C, Watts R, et al. Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Blood 2010; 116:4192-201.
38. Tran MA, Smith CD, Kester M, Robertson GP. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin Cancer Res 2008; 14:3571-81.
39. Kester M, Heakal Y, Fox T, Sharma A, Robertson GP, Morgan TT, et al. Calcium phosphate nanocomposite particles for in vitro imaging and encapsulated chemotherapeutic drug delivery to cancer cells. Nano Lett 2008; 8:4116-21.
40. Stover TC, Kim YS, Lowe TL, Kester M. Thermoresponsive and biodegradable linear-dendritic nanoparticles for targeted and sustained release of a pro-apoptotic drug. Biomaterials 2008; 29:359-69.
41. Zolnik BS, Stern ST, Kaiser JM, Heakal Y, Clogston JD, Kester M, et al. Rapid distribution of liposomal short-chain ceramide in vitro and in vivo. Drug Metab Dispos 2008; 36:1709-15.
42. Khazanov E, Priev A, Shillemans JP, Barenholz Y. Physicochemical and biological characterization of ceramide-containing liposomes: paving the way to ceramide therapeutic application. Langmuir 2008; 24:6965-80.
43. Struckhoff AP, Bittman R, Burow ME, Clejan S, Elliott S, Hammond T, et al. Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. J Pharmacol Exp Ther 2004; 309:523-32.
44. Senkal CE, Ponnusamy S, Rossi MJ, Sundararaj K, Szulc Z, Bielawski J, et al. Potent antitumor activity of a novel cationic pyridinium-ceramide alone or in combination with gemcitabine against human head and neck squamous cell carcinomas in vitro and in vivo. J Pharmacol Exp Ther 2006; 317:1188-99.
45. Dindo D, Dahm F, Szulc Z, Bielawska A, Obeid LM, Hannun YA, et al. Cationic long-chain ceramide LCL-30 induces cell death by mitochondrial targeting in SW403 cells. Mol Cancer Ther 2006; 5:1520-9.
46. Dahm F, Bielawska A, Nocito A, Georgiev P, Szulc ZM, Bielawski J, et al. Mitochondrially targeted ceramide LCL-30 inhibits colorectal cancer in mice. Br J Cancer 2008; 98:98-105.
47. Rylova SN, Somova OG, Dyatlovitskaya EV. Comparative investigation of sphingoid bases and fatty acids in ceramides and sphingomyelins from human ovarian malignant tumors and normal ovary. Biochemistry (Mosc) 1998; 63:1057-60.
48. Riboni L, Campanella R, Bassi R, Villani R, Gaini SM, Martinelli-Boneschi F, et al. Ceramide levels are inversely associated with malignant progression of human glial tumors. Glia 2002; 39:105-13.
49. Merchant TE, Kasimos JN, de Graaf PW, Minsky BD, Gierke LW, Glonek T. Phospholipid profiles of human colon cancer using 31P magnetic resonance spectroscopy. Int J Colorectal Dis 1991; 6:121-6.
50. Selzner M, Bielawska A, Morse MA, Rüdiger HA, Sindram D, Hannun YA, et al. Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res 2001; 61:1233-40.
51. Karahatay S, Thomas K, Koybasi S, Senkal CE, Elojeimy S, Liu X, et al. Clinical relevance of ceramide metabolism in the pathogenesis of human head and neck squamous cell carcinoma (HNSCC): attenuation of C(18)-ceramide in HNSCC tumors correlates with lymphovascular invasion and nodal metastasis. Cancer Lett 2007; 256:101-11.
52. Schiffmann S, Sandner J, Birod K, Wobst I, Angioni C, Ruckhäberle E, et al. Ceramide synthases and ceramide levels are increased in breast cancer tissue. Carcinogenesis 2009; 30:745-52.
53. Senkal CE, Ponnusamy S, Bielawski J, Hannun YA, Ogretmen B. Antiapoptotic roles of ceramide-synthase-6-generated C16-ceramide via selective regulation of the ATF6/CHOP arm of ER-stress-response pathways. Faseb J 2010; 24:296-308.
54. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357:539-45.
55. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-7.
56. Sun Y, Fox T, Adhikary G, Kester M, Pearlman E. Inhibition of corneal inflammation by liposomal delivery of short-chain, C-6 ceramide. J Leukoc Biol 2008; 83:1512-21.
57. Kitatani K, Sheldon K, Anelli V, Jenkins RW, Sun Y, Grabowski GA, et al. Acid beta-glucosidase 1 counteracts p38delta-dependent induction of interleukin-6: possible role for ceramide as an anti-inflammatory lipid. J Biol Chem 2009; 284:12979-88.
58. Nava VE, Hobson JP, Murthy S, Milstien S, Spiegel S. Sphingosine kinase type 1 promotes estrogendependent tumorigenesis of breast cancer MCF-7 cells. Exp Cell Res 2002; 281:115-27.
59. Wang F, Van Brocklyn JR, Edsall L, Nava VE, Spiegel S. Sphingosine-1-phosphate inhibits motility of human breast cancer cells independently of cell surface receptors. Cancer Res 1999; 59:6185-91.
60. Payne SG, Milstien S, Spiegel S. Sphingosine-1-phosphate: dual messenger functions. FEBS Lett 2002; 531:54-7.
61. Van Brocklyn JR, Jackson CA, Pearl DK, Kotur MS, Snyder PJ, Prior TW. Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol 2005; 64:695-705.
62. Illuzzi G, Bernacchioni C, Aureli M, Prioni S, Frera G, Donati C, et al. Sphingosine kinase mediates resistance to the synthetic retinoid N-(4-hydroxyphenyl) retinamide in human ovarian cancer cells. J Biol Chem 2010; 285:18594-602.
63. Guillermet-Guibert J, Davenne L, Pchejetski D, Saint-Laurent N, Brizuela L, Guilbeau-Frugier C, et al. Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. Mol Cancer Ther 2009; 8:809-20.
64. Tilly JL, Kolesnick RN. Sphingolipids, apoptosis, cancer treatments and the ovary: investigating a crime against female fertility. Biochim Biophys Acta 2002; 1585:135-8.
65. Perez GI, Knudson CM, Leykin L, Korsmeyer SJ, Tilly JL. Apoptosis-associated signaling pathways are required for chemotherapy-mediated female germ cell destruction. Nat Med 1997; 3:1228-32.
66. Snider AJ, Orr Gandy KA, Obeid LM. Sphingosine kinase: Role in regulation of bioactive sphingolipid mediators in inflammation. Biochimie 2010; 92:707-15.
67. Pettus BJ, Bielawski J, Porcelli AM, Reames DL, Johnson KR, Morrow J, et al. The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNFalpha. Faseb J 2003; 17:1411-21.
68. Hsieh HL, Wu CB, Sun CC, Liao CH, Lau YT, Yang CM. Sphingosine-1- phosphate induces COX-2 expression via PI3K/Akt and p42/p44 MAPK pathways in rat vascular smooth muscle cells. J Cell Physiol 2006; 207:757-66.
69. Thamilselvan V, Li W, Sumpio BE, Basson MD. Sphingosine-1-phosphate stimulates human Caco-2 intestinal epithelial proliferation via p38 activation and activates ERK by an independent mechanism. In Vitro Cell Dev Biol Anim 2002; 38:246-53.
70. Catarzi S, Giannoni E, Favilli F, Meacci E, Iantomasi T, Vincenzini MT. Sphingosine 1-phosphate stimulation of NADPH oxidase activity: relationship with platelet-derived growth factor receptor and c-Src kinase. Biochim Biophys Acta 2007; 1770:872-83.
71. Endo A, Nagashima K, Kurose H, Mochizuki S, Matsuda M, Mochizuki N. Sphingosine 1-phosphate induces membrane ruffling and increases motility of human umbilical vein endothelial cells via vascular endothelial growth factor receptor and CrkII. J Biol Chem 2002; 277:23747-54.
72. Heo K, Park KA, Kim YH, Kim SH, Oh YS, Kim IH, et al. Sphingosine 1-phosphate induces vascular endothelial growth factor expression in endothelial cells. BMB Rep 2009; 42:685-90.
73. Igarashi J, Erwin PA, Dantas AP, Chen H, Michel T. VEGF induces S1P1 receptors in endothelial cells: Implications for cross-talk between sphingolipid and growth factor receptors. Proc Natl Acad Sci USA 2003; 100:10664-9.
74. Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, et al. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion and angiogenesis in multiple tumor lineages. Cancer Cell 2006; 9:225-38.
75. Spiegel S, English D, Milstien S. Sphingosine 1-phosphate signaling: providing cells with a sense of direction. Trends Cell Biol 2002; 12:236-42.
76. Chalfant CE, Spiegel S. Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signaling. J Cell Sci 2005; 118:4605-12.
77. Pyne S, Lee SC, Long J, Pyne NJ. Role of sphingosine kinases and lipid phosphate phosphatases in regulating spatial sphingosine 1-phosphate signalling in health and disease. Cell Signal 2009; 21:14-21.
78. Nishimura H, Akiyama T, Irei I, Hamazaki S, Sadahira Y. Cellular localization of sphingosine-1-phosphate receptor 1 expression in the human central nervous system. J Histochem Cytochem 2010; 58:847-56.
79. Watson C, Long JS, Orange C, Tannahill CL, Mallon E, McGlynn LM, et al. High expression of Sphingosine 1-Phosphate receptors, S1P1 and S1P3, Sphingosine kinase 1 and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. Am J Pathol 2010; 177:2205-15.
80. Akao Y, Banno Y, Nakagawa Y, Hasegawa N, Kim TJ, Murate T, et al. High expression of sphingosine kinase 1 and S1P receptors in chemotherapy-resistant prostate cancer PC3 cells and their camptothecin-induced upregulation. Biochem Biophys Res Commun 2006; 342:1284-90.
81. Young N, Van Brocklyn JR. Roles of sphingosine-1-phosphate (S1P) receptors in malignant behavior of glioma cells. Differential effects of S1P2 on cell migration and invasiveness. Exp Cell Res 2007; 313:1615-27.
82. Long JS, Fujiwara Y, Edwards J, Tannahill CL, Tigyi G, Pyne S, et al. Sphingosine 1-phosphate receptor 4 uses HER2 (ErbB2) to regulate extracellular signal regulated kinase-1/2 in MDA-MB-453 breast cancer cells. J Biol Chem 2010; 285:35957-66.
83. Long JS, Edwards J, Watson C, Tovey S, Mair KM, Schiff R, et al. Sphingosine kinase 1 induces tolerance to human epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in response to sphingosine 1-phosphate in estrogen receptor-positive breast cancer cells. Mol Cell Biol 2010; 30:3827-41.
84. Kothapalli R, Kusmartseva I, Loughran TP. Characterization of a human sphingosine-1-phosphate receptor gene (S1P5) and its differential expression in LGL leukemia. Biochim Biophys Acta 2002; 1579:117-23.
85. Shah MV, Zhang R, Irby R, Kothapalli R, Liu X, Arrington T, et al. Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes. Blood 2008; 112:770-81.
86. Levi M, Meijler MM, Gomez-Munoz A, Zor T. Distinct receptor-mediated activities in macrophages for natural ceramide-1-phosphate (C1P) and for phospho-ceramide analogue-1 (PCERA-1). Mol Cell Endocrinol 2010; 314:248-55.
87. Pettus BJ, Kitatani K, Chalfant CE, Taha TA, Kawamori T, Bielawski J, et al. The coordination of prostaglandin E2 production by sphingosine-1-phosphate and ceramide-1-phosphate. Mol Pharmacol 2005; 68:330-5.
88. Lamour NF, Stahelin RV, Wijesinghe DS, Maceyka M, Wang E, Allegood JC, et al. Ceramide kinase uses ceramide provided by ceramide transport protein: localization to organelles of eicosanoid synthesis. J Lipid Res 2007; 48:1293-304.
89. Liu YY, Han TY, Giuliano AE, Cabot MC. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J Biol Chem 1999; 274:1140-6.
90. Morjani H, Aouali N, Belhoussine R, Veldman RJ, Levade T, Manfait M. Elevation of glucosylceramide in multidrug-resistant cancer cells and accumulation in cytoplasmic droplets. Int J Cancer 2001; 94:157-65.
91. Liu Y, Chen Y, Momin A, Shaner R, Wang E, Bowen NJ, et al. Elevation of sulfatides in ovarian cancer: an integrated transcriptomic and lipidomic analysis including tissue-imaging mass spectrometry. Mol Cancer 2010; 9:186.
92. Morichika H, Hamanaka Y, Tai T, Ishizuka I. Sulfatides as a predictive factor of lymph node metastasis in patients with colorectal adenocarcinoma. Cancer 1996; 78:43-7.
93. Hiraiwa N, Fukuda Y, Imura H, Tadano-Aritomi K, Nagai K, Ishizuka I, et al. Accumulation of highly acidic sulfated glycosphingolipids in human hepatocellular carcinoma defined by a series of monoclonal antibodies. Cancer Res 1990; 50:2917-28.
94. Sakakibara N, Gasa S, Kamio K, Makita A, Nonomura K, Togashi M, et al. Distinctive glycolipid patterns in Wilms' tumor and renal cell carcinoma. Cancer Lett 1991; 57:187-92.
95. Gnewuch C, Jaques G, Havemann K, Wiegandt H. Re-assessment of acidic glycosphingolipids in smallcell-lung-cancer tissues and cell lines. Int J Cancer Suppl 1994; 8:125-6.
96. Boggs JM, Gao W, Zhao J, Park HJ, Liu Y, Basu A. Participation of galactosylceramide and sulfatide in glycosynapses between oligodendrocyte or myelin membranes. FEBS Lett 2010; 584:1771-8.
97. Zhong Wu X, Honke K, Long Zhang Y, Liang Zha X, Taniguchi N. Lactosylsulfatide expression in hepatocellular carcinoma cells enhances cell adhesion to vitronectin and intrahepatic metastasis in nude mice. Int J Cancer 2004; 110:504-10.
98. Hakomori S, Handa K. Glycosphingolipid-dependent cross-talk between glycosynapses interfacing tumor cells with their host cells: essential basis to define tumor malignancy. FEBS Lett 2002; 531:88-92.
99. Hakomori S. Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. Cancer Res 1985; 45:2405-14.
100. Hanai N, Nakamura K, Shitara K. Recombinant antibodies against ganglioside expressed on tumor cells. Cancer Chemother Pharmacol 2000; 46:13-7.
101. Li R, Villacreses N, Ladisch S. Human tumor gangliosides inhibit murine immune responses in vivo. Cancer Res 1995; 55:211-4.
102. Bharti AC, Singh SM. Induction of apoptosis in bone marrow cells by gangliosides produced by a T cell lymphoma. Immunol Lett 2000; 72:39-48.
103. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001; 19:2370-80.
104. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15:5323-37.
105. Fernandez LE, Gabri MR, Guthmann MD, Gomez RE, Gold S, Fainboim L, et al. NGcGM3 ganglioside: a privileged target for cancer vaccines. Clin Dev Immunol 2010; 2010:814397.
106. Modrak DE, Lew W, Goldenberg DM, Blumenthal R. Sphingomyelin potentiates chemotherapy of human cancer xenografts. Biochem Biophys Res Commun 2000; 268:603-6.
107. Lemonnier LA, Dillehay DL, Vespremi MJ, Abrams J, Brody E, Schmelz EM. Sphingomyelin in the suppression of colon tumors: prevention versus intervention. Arch Biochem Biophys 2003; 419:129-38.
108. Modrak DE, Cardillo TM, Newsome GA, Goldenberg DM, Gold DV. Synergistic interaction between sphingomyelin and gemcitabine potentiates ceramide-mediated apoptosis in pancreatic cancer. Cancer Res 2004; 64:8405-10.
109. Dillehay DL, Webb SK, Schmelz EM, Merrill AH Jr. Dietary sphingomyelin inhibits 1,2-dimethylhydrazine-induced colon cancer in CF1 mice. J Nutr 1994; 124:615-20.
110. Schmelz EM, Sullards MC, Dillehay DL, Merrill AH Jr. Colonic cell proliferation and aberrant crypt foci formation are inhibited by dairy glycosphingolipids in 1,2-dimethylhydrazine-treated CF1 mice. J Nutr 2000; 130:522-7.
111. Kandyba AG, Somova OG, Kozlov AM, Zubova ES, Dudnik LB, Alessenko AV, et al. Sphingolipids of transplantable rat nephroma-RA. Biochemistry (Mosc) 2000; 65:703-6.
112. Kandyba AG, Kobliakov VA, Kozlov AM, Nagaev IY, Shevchenko VP, Dyatlovitskaya EV. Dihydroceramide desaturase activity in tumors. Biochemistry (Mosc) 2002; 67:597-9.
113. Ohta H, Sweeney EA, Masamune A, Yatomi Y, Hakomori S, Igarashi Y. Induction of apoptosis by sphingosine in human leukemic HL-60 cells: a possible endogenous modulator of apoptotic DNA fragmentation occurring during phorbol ester-induced differentiation. Cancer Res 1995; 55:691-7.
114. Jarvis WD, Fornari FA, Traylor RS, Martin HA, Kramer LB, Erukulla RK, et al. Induction of apoptosis and potentiation of ceramide-mediated cytotoxicity by sphingoid bases in human myeloid leukemia cells. J Biol Chem 1996; 271:8275-84.
115. Ahn EH, Schroeder JJ. Induction of apoptosis by sphingosine, sphinganine and C(2)-ceramide in human colon cancer cells, but not by C(2)-dihydroceramide. Anticancer Res 2010; 30:2881-4.
116. Noda T, Iwai S, Hamada M, Fujita Y, Yura Y. Induction of apoptosis of detached oral squamous cell carcinoma cells by safingol. Possible role of Bim, focal adhesion kinase and endonuclease G. Apoptosis 2009; 14:287-97.
117. Coward J, Ambrosini G, Musi E, Truman JP, Haimovitz-Friedman A, Allegood JC, et al. Safingol (L-threo-sphinganine) induces autophagy in solid tumor cells through inhibition of PKC and the PI3-kinase pathway. Autophagy 2009; 5:184-93.
118. LaMontagne K, Littlewood-Evans A, Schnell C, O'Reilly T, Wyder L, Sanchez T, et al. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res 2006; 66:221-31.
119. Schmid G, Guba M, Ischenko I, Papyan A, Joka M, Schrepfer S, et al. The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1. J Cell Biochem 2007; 101:259-70.
120. Matsuoka Y, Nagahara Y, Ikekita M, Shinomiya T. A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br J Pharmacol 2003; 138:1303-12.
121. Azuma H, Takahara S, Horie S, Muto S, Otsuki Y, Katsuoka Y. Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J Urol 2003; 169:2372-7.
122. Sonoda Y, Yamamoto D, Sakurai S, Hasegawa M, Aizu-Yokota E, Momoi T, et al. FTY720, a novel immunosuppressive agent, induces apoptosis in human glioma cells. Biochem Biophys Res Commun 2001; 281:282-8.
123. Wang JD, Takahara S, Nonomura N, Ichimaru N, Toki K, Azuma H, et al. Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation. Prostate 1999; 40:50-5.
124. Knapp P, Baranowski M, Knapp M, Zabielski P, Blachnio-Zabielska AU, Gorski J. Altered sphingolipid metabolism in human endometrial cancer. Prostaglandins Other Lipid Mediat 2010; 92:62-6.
125. Marasas WF. Discovery and occurrence of the fumonisins: a historical perspective. Environ Health Perspect 2001; 109:239-43.
126. He Q, Bhandari N, Sharma RP. Fumonisin B(1) alters sphingolipid metabolism and tumor necrosis factor alpha expression in heart and lung of mice. Life Sci 2002; 71:2015-23.
127. Eichler FS, Hornemann T, McCampbell A, Kuljis D, Penno A, Vardeh D, et al. Overexpression of the wild-type SPT1 subunit lowers desoxysphingolipid levels and rescues the phenotype of HSAN1. J Neurosci 2009; 29:14646-51.
128. Symolon H, Schmelz EM, Dillehay DL, Merrill AH Jr. Dietary soy sphingolipids suppress tumorigenesis and gene expression in 1,2- dimethylhydrazine-treated CF1 mice and ApcMin/+ mice. J Nutr 2004; 134:1157-61.
129. Fyrst H, Oskouian B, Bandhuvula P, Gong Y, Byun HS, Bittman R, et al. Natural sphingadienes inhibit Akt-dependent signaling and prevent intestinal tumorigenesis. Cancer Res 2009; 69:9457-64.
130. Kraveka JM, Li L, Szulc ZM, Bielawski J, Ogretmen B, Hannun YA, et al. Involvement of dihydroceramide desaturase in cell cycle progression in human neuroblastoma cells. J Biol Chem 2007; 282:16718-28.
131. Signorelli P, Munoz-Olaya JM, Gagliostro V, Casas J, Ghidoni R, Fabrias G. Dihydroceramide intracellular increase in response to resveratrol treatment mediates autophagy in gastric cancer cells. Cancer Lett 2009; 282:238-43.
132. Mahdy AE, Cheng JC, Li J, Elojeimy S, Meacham WD, Turner LS, et al. Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer. Mol Ther 2009; 17:430-8.
133. Liu X, Cheng JC, Turner LS, Elojeimy S, Beckham TH, Bielawska A, et al. Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy. Expert Opin Ther Targets 2009; 13:1449-58.
134. Samsel L, Zaidel G, Drumgoole HM, Jelovac D, Drachenberg C, Rhee JG, et al. The ceramide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts. Prostate 2004; 58:382-93.
135. Holman DH, Turner LS, El-Zawahry A, Elojeimy S, Liu X, Bielawski J, et al. Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells. Cancer Chemother Pharmacol 2008; 61:231-42.
136. Morales A, Paris R, Villanueva A, Llacuna L, Garcia-Ruiz C, Fernandez-Checa JC. Pharmacological inhibition or small interfering RNA targeting acid ceramidase sensitizes hepatoma cells to chemotherapy and reduces tumor growth in vivo. Oncogene 2007; 26:905-16.
137. Raisova M, Goltz G, Bektas M, Bielawska A, Riebeling C, Hossini AM, et al. Bcl-2 overexpression prevents apoptosis induced by ceramidase inhibitors in malignant melanoma and HaCaT keratinocytes. FEBS Lett 2002; 516:47-52.
138. Alphonse G, Bionda C, Aloy MT, Ardail D, Rousson R, Rodriguez-Lafrasse C. Overcoming resistance to gammarays in squamous carcinoma cells by poly-drug elevation of ceramide levels. Oncogene 2004; 23:2703-15.
139. Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind S, et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1- phosphate. Nature 1996; 381:800-3.
140. Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 2009; 325:1254-7.
141. Maceyka M, Sankala H, Hait NC, Le Stunff H, Liu H, Toman R, et al. SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J Biol Chem 2005; 280:37118-29.
142. Igarashi N, Okada T, Hayashi S, Fujita T, Jahangeer S, Nakamura S. Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. J Biol Chem 2003; 278:46832-9.
143. French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 2003; 63:5962-9.
144. Ruckhaberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S, et al. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat 2008; 112:41-52.
145. Duan RD, Nilsson A. Metabolism of sphingolipids in the gut and its relation to inflammation and cancer development. Prog Lipid Res 2009; 48:62-72.
146. Kawamori T, Osta W, Johnson KR, Pettus BJ, Bielawski J, Tanaka T, et al. Sphingosine kinase 1 is upregulated in colon carcinogenesis. Faseb J 2006; 20:386-8.
147. Johnson KR, Johnson KY, Crellin HG, Ogretmen B, Boylan AM, Harley RA, et al. Immunohistochemical distribution of sphingosine kinase 1 in normal and tumor lung tissue. J Histochem Cytochem 2005; 53:1159-66.
148. Bayerl MG, Bruggeman RD, Conroy EJ, Hengst JA, King TS, Jimenez M, et al. Sphingosine kinase 1 protein and mRNA are overexpressed in non-Hodgkin lymphomas and are attractive targets for novel pharmacological interventions. Leuk Lymphoma 2008; 49:948-54.
149. Bektas M, Jolly PS, Muller C, Eberle J, Spiegel S, Geilen CC. Sphingosine kinase activity counteracts ceramidemediated cell death in human melanoma cells: role of Bcl-2 expression. Oncogene 2005; 24:178-87.
150. French KJ, Upson JJ, Keller SN, Zhuang Y, Yun JK, Smith CD. Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther 2006; 318:596-603.
151. Bonhoure E, Pchejetski D, Aouali N, Morjani H, Levade T, Kohama T, et al. Overcoming MDRassociated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia 2006; 20:95-102.
152. Bonhoure E, Lauret A, Barnes DJ, Martin C, Malavaud B, Kohama T, et al. Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells. Leukemia 2008; 22:971-9.
153. Cakir Z, Saydam G, Sahin F, Baran Y. The roles of bioactive sphingolipids in resveratrol-induced apoptosis in HL60: acute myeloid leukemia cells. J Cancer Res Clin Oncol 2010; In press.
154. Paugh SW, Paugh BS, Rahmani M, Kapitonov D, Almenara JA, Kordula T, et al. A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood 2008; 112:1382-91.
155. Kapitonov D, Allegood JC, Mitchell C, Hait NC, Almenara JA, Adams JK, et al. Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis and suppresses growth of human glioblastoma cells and xenografts. Cancer Res 2009; 69:6915-23.
156. Shirahama T, Sweeney EA, Sakakura C, Singhal AK, Nishiyama K, Akiyama S, et al. In vitro and in vivo induction of apoptosis by sphingosine and N,Ndimethylsphingosine in human epidermoid carcinoma KB-3-1 and its multidrug-resistant cells. Clin Cancer Res 1997; 3:257-64.
157. Sweeney EA, Sakakura C, Shirahama T, Masamune A, Ohta H, Hakomori S, et al. Sphingosine and its methylated derivative N,N-dimethylsphingosine (DMS) induce apoptosis in a variety of human cancer cell lines. Int J Cancer 1996; 66:358-66.
158. Beljanski V, Knaak C, Smith CD. A novel sphingosine kinase inhibitor induces autophagy in tumor cells. J Pharmacol Exp Ther 2010; 333:454-64.
159. Antoon JW, White MD, Meacham WD, Slaughter EM, Muir SE, Elliott S, et al. Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. Endocrinology 2010; 151:5124-35.
160. Oskouian B, Sooriyakumaran P, Borowsky AD, Crans A, Dillard-Telm L, Tam
161. Colie S, Van Veldhoven PP, Kedjouar B, Bedia C, Albinet V, Sorli SC, et al. Disruption of sphingosine 1-phosphate lyase confers resistance to chemotherapy and promotes oncogenesis through Bcl-2/Bcl-xL upregulation. Cancer Res 2009; 69:9346-53.
162. Sugiura M, Kono K, Liu H, Shimizugawa T, Minekura H, Spiegel S, et al. Ceramide kinase, a novel lipid kinase. Molecular cloning and functional characterization. J Biol Chem 2002; 277:23294-300.
163. Murakami M, Ito H, Hagiwara K, Yoshida K, Sobue S, Ichihara M, et al. ATRA inhibits ceramide kinase transcription in a human neuroblastoma cell line, SH-SY5Y cells: the role of COUP-TFI. J Neurochem 2010; 112:511-20.
164. Ruckhaberle E, Karn T, Rody A, Hanker L, Gätje R, Metzler D, et al. Gene expression of ceramide kinase, galactosyl ceramide synthase and ganglioside GD3 synthase is associated with prognosis in breast cancer. J Cancer Res Clin Oncol 2009; 135:1005-13.
165. Mitra P, Maceyka M, Payne SG, Lamour N, Milstien S, Chalfant CE, et al. Ceramide kinase regulates growth and survival of A549 human lung adenocarcinoma cells. FEBS Lett 2007; 581:735-40.
166. Date T, Mitsutake S, Igarashi Y. Ceramide kinase expression is altered during macrophage-like cell differentiation of the leukemia cell line HL-60. In Vitro Cell Dev Biol Anim 2007; 43:321-3.
167. Gustafsson K, Sander B, Bielawski J, Hannun YA, Flygare J. Potentiation of cannabinoid-induced cytotoxicity in mantle cell lymphoma through modulation of ceramide metabolism. Mol Cancer Res 2009; 7:1086-98.
168. Wang H, Giuliano AE, Cabot MC. Enhanced de novo ceramide generation through activation of serine palmitoyltransferase by the P-glycoprotein antagonist SDZ PSC 833 in breast cancer cells. Mol Cancer Ther 2002; 1:719-26.
169. Sauane M, Su ZZ, Dash R, et al. Ceramide plays a prominent role in MDA-7/IL-24-induced cancerspecific apoptosis. J Cell Physiol 2010; 222:546-55.
170. Merrill AH Jr. De novo sphingolipid biosynthesis: a necessary, but dangerous, pathway. J Biol Chem 2002; 277:25843-6.
171. Futerman AH, Riezman H. The ins and outs of sphingolipid synthesis. Trends Cell Biol 2005; 15:312-8.
172. Pewzner-Jung Y, Ben-Dor S, Futerman AH. When do Lasses (longevity assurance genes) become CerS (ceramide synthases)? Insights into the regulation of ceramide synthesis. J Biol Chem 2006; 281:25001-5.
173. Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z, Kolesnick R. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell 1995; 82:405-14.
174. Kolesnick RN. Thyrotropin-releasing hormone and phorbol esters induce phosphatidylcholine synthesis in GH3 pituitary cells. Evidence for stimulation via protein kinase C. J Biol Chem 1987; 262:14525-30.
175. Kolesnick RN, Clegg S. 1,2-Diacylglycerols, but not phorbol esters, activate a potential inhibitory pathway for protein kinase C in GH3 pituitary cells. Evidence for involvement of a sphingomyelinase. J Biol Chem 1988; 263:6534-7.
176. Morita Y, Perez GI, Paris F, Miranda SR, Ehleiter D, Haimovitz-Friedman A, et al. Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat Med 2000; 6:1109-14.
177. Rahmani M, Reese E, Dai Y, Bauer C, Payne SG, Dent P, et al. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res 2005; 65:2422-32.
178. Jaffrezou JP, Levade T, Bettaieb A, Andrieu N, Bezombes C, Maestre N, et al. Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. EMBO J 1996; 15:2417-24.
179. Bezombes C, Segui B, Cuvillier O, Bruno AP, Uro-Coste E, Gouazé V, et al. Lysosomal sphingomyelinase is not solicited for apoptosis signaling. Faseb J 2001; 15:297-9.
180. Bezombes C, de Thonel A, Apostolou A, Louat T, Jaffrézou JP, Laurent G, et al. Overexpression of protein kinase Czeta confers protection against antileukemic drugs by inhibiting the redox-dependent sphingomyelinase activation. Mol Pharmacol 2002; 62:1446-55.
181. Santana P, Pena LA, Haimovitz-Friedman A, Martin S, Green D, McLoughlin M, et al. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 1996; 86:189-99.
182. Kinjo T, Kowalczyk P, Kowalczyk M, Walaszek Z, Nishimaki T, Slaga TJ, et al. Desipramine inhibits the growth of a mouse skin squamous cell carcinoma cell line and affects glucocorticoid receptor-mediated transcription. Mol Carcinog 2009; 48:1123-30.
183. Arimochi H, Morita K. Desipramine induces apoptotic cell death through nonmitochondrial and mitochondrial pathways in different types of human colon carcinoma cells. Pharmacology 2008; 81:164-72.
184. Lu T, Huang CC, Lu YC, Lin KL, Liu SI, Wang BW, et al. Desipramine-induced Ca-independent apoptosis in Mg63 human osteosarcoma cells: dependence on p38 mitogen-activated protein kinase-regulated activation of caspase 3. Clin Exp Pharmacol Physiol 2009; 36:297-303.
185. Huang CJ, Cheng HH, Chou CT, Kuo CC, Lu YC, Tseng LL, et al. Desipramine-induced Ca2+ movement and cytotoxicity in PC3 human prostate cancer cells. Toxicol In Vitro 2007; 21:449-56.
186. Takahashi E, Inanami O, Asanuma T, Kuwabara M. Effects of ceramide inhibition on radiation-induced apoptosis in human leukemia MOLT-4 cells. J Radiat Res (Tokyo) 2006; 47:19-25.
187. Smith EL, Schuchman EH. Acid sphingomyelinase overexpression enhances the antineoplastic effects of irradiation in vitro and in vivo. Mol Ther 2008; 16:1565-71.
188. Grammatikos G, Teichgraber V, Carpinteiro A, Trarbach T, Weller M, Hengge UR, et al. Overexpression of acid sphingomyelinase sensitizes glioma cells to chemotherapy. Antioxid Redox Signal 2007; 9:1449-56.
189. Cheng Y, Wu J, Hertervig E, Lindgren S, Duan D, Nilsson A, et al. Identification of aberrant forms of alkaline sphingomyelinase (NPP7) associated with human liver tumorigenesis. Br J Cancer 2007; 97:1441-8.
190. Cheng Y, Ohlsson L, Duan RD. Psyllium and fat in diets differentially affect the activities and expressions of colonic sphingomyelinases and caspase in mice. Br J Nutr 2004; 91:715-23.
191. Duan RD, Cheng Y, Hansen G, Hertervig E, Liu JJ, Syk I, et al. Purification, localization and expression of human intestinal alkaline sphingomyelinase. J Lipid Res 2003; 44:1241-50.
192. Andersson D, Liu JJ, Nilsson A, Duan RD. Ursolic acid inhibits proliferation and stimulates apoptosis in HT29 cells following activation of alkaline sphingomyelinase. Anticancer Res 2003; 23:3317-22.
193. Cheng Y, Kozubek A, Ohlsson L, Sternby B, Duan RD. Curcumin decreases acid sphingomyelinase activity in colon cancer Caco-2 cells. Planta Med 2007; 73:725-30.
194. Meng A, Luberto C, Meier P, Bai A, Yang X, Hannun YA, et al. Sphingomyelin synthase as a potential target for D609-induced apoptosis in U937 human monocytic leukemia cells. Exp Cell Res 2004; 292:385-92.
195. Bai A, Meier GP, Wang Y, Luberto C, Hannun YA, Zhou D. Prodrug modification increases potassium tricyclo[5.2.1.0(2,6)]-decan-8-yl dithiocarbonate (D609) chemical stability and cytotoxicity against U937 leukemia cells. J Pharmacol Exp Ther 2004; 309:1051-9.
196. Bleicher RJ, Cabot MC. Glucosylceramide synthase and apoptosis. Biochim Biophys Acta 2002; 1585:172-8.
197. Liu YY, Han TY, Giuliano AE, Cabot MC. Ceramide glycosylation potentiates cellular multidrug resistance. Faseb J 2001; 15:719-30.
198. Uchida Y, Itoh M, Taguchi Y, Yamaoka S, Umehara H, Ichikawa S, et al. Ceramide reduction and transcriptional upregulation of glucosylceramide synthase through doxorubicin-activated Sp1 in drug-resistant HL-60/ADR cells. Cancer Res 2004; 64:6271-9.
199. Ruckhaberle E, Karn T, Hanker L, Gätje R, Metzler D, Holtrich U, et al. Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer. J Cancer Res Clin Oncol 2009; 135:81-90.
200. Liu YY, Han TY, Yu JY, Bitterman A, Le A, Giuliano AE, et al. Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells. J Lipid Res 2004; 45:933-40.
201. Gouaze V, Yu JY, Bleicher RJ, Han TY, Liu YY, Wang H, et al. Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol Cancer Ther 2004; 3:633-9.
202. Uchida Y, Murata S, Schmuth M, Behne MJ, Lee JD, Ichikawa S, et al. Glucosylceramide synthesis and synthase expression protect against ceramide-induced stress. J Lipid Res 2002; 43:1293-302.
203. Weiss M, Hettmer S, Smith P, Ladisch S. Inhibition of melanoma tumor growth by a novel inhibitor of glucosylceramide synthase. Cancer Res 2003; 63:3654-8.
204. Gouaze V, Liu YY, Prickett CS, Yu JY, Giuliano AE, Cabot MC. Glucosylceramide synthase blockade downregulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. Cancer Res 2005; 65:3861-7.
205. Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines. J Natl Cancer Inst 1999; 91:1138-46.
206. Liu YY, Gupta V, Patwardhan GA, Bhinge K, Zhao Y, Bao J, et al. Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling. Mol Cancer 2010; 9:145.
207. Byrnes RW, Cotter D, Maer A, Li J, Nadeau D, Subramaniam S. An editor for pathway drawing and data visualization in the Biopathways Workbench. BMC Syst Biol 2009; 3:99.